NHS England has expanded a rapid genomic test for brain tumours to five specialist centres, part of a pilot it says can turn some diagnoses around in days rather than weeks. The programme, announced on 25 September, is backed by more than £2m over two years and is being described as phase one.
That last phrase matters. Phase one means five centres, not every hospital. It means a pilot, not a national service. And it means the claim to watch is not whether genomic sequencing sounds impressive. It is whether the test shortens the time from sample to answer for the patients who need it.
What is being piloted
Genomic testing looks at the molecular make-up of a tumour. For brain tumours, that information can help clinicians distinguish between tumour types, identify markers that influence treatment, and decide whether a patient should be offered a particular drug or clinical trial.
At present, a brain tumour diagnosis often depends on imaging, surgery or biopsy, and tissue analysis. Some molecular tests can take weeks to return, especially when samples are sent to specialist laboratories. The NHS pilot is designed to bring rapid genomic testing closer to the diagnostic pathway, so that molecular results arrive sooner.
NHS England says the initial network covers five specialist centres. The exact list and referral criteria will matter to patients and clinicians. BBC News has reported on the Newcastle element, with Newcastle Hospitals and Newcastle University involved in the pilot. That local focus is useful because it shows what the programme looks like on the ground: laboratory capacity, clinical teams, and a pathway for samples to move quickly.
Days, not weeks — but for whom?
The headline promise is faster diagnosis. 'Days not weeks' is a sensible ambition for a test that can shape surgery, radiotherapy, chemotherapy or trial eligibility. But the claim needs unpacking. Faster than what? For which tumour types? Measured from scan, biopsy, sample receipt, or result? And for how many patients?
Those questions are not quibbles. In diagnostics, average turnaround can hide wide variation. A pathway that returns some results in days while others still wait weeks may improve care without transforming the overall experience. The pilot’s value will depend on whether it reaches the patients whose treatment decisions are most time-sensitive.
There is also a capacity question. Genomic sequencing is not a single machine that produces an answer on demand. It needs tissue of sufficient quality, laboratory staff, bioinformatics, and clinical scientists who can interpret the result. Five centres can create a hub-and-spoke model, but samples still have to travel, and results still have to reach a multidisciplinary team meeting.
What it means for NHS waiting lists
This is not an A&E overcrowding story, and it should not be sold as one. Brain tumour patients are a small fraction of the overall NHS waiting list, but their delays carry a particular weight: a suspected brain tumour can mean headaches, seizures, personality changes, or neurological deficits, and uncertainty while waiting is part of the harm.
A faster molecular diagnosis could reduce some of that uncertainty and help treatment start sooner. It could also reduce repeat tests or avoid some invasive procedures if molecular information can be obtained from less tissue. Those are plausible benefits, not proven ones in this pilot.
The wider waiting-list picture is determined by referral volumes, scanner capacity, theatre time, pathology staffing, and oncology capacity. A five-centre genomic pilot will not fix those constraints. It may, however, show whether a targeted investment in molecular diagnostics can shorten one part of the pathway enough to matter.
The evidence to watch
NHS England’s announcement is a service pilot, not a peer-reviewed trial. That does not make it unimportant. It means the evidence will arrive in stages: how many patients were tested, how long results took, how often the test changed diagnosis or treatment, and whether clinicians found it usable.
Patients and clinicians should also ask how the pilot handles equity. If rapid genomic testing depends on being near one of five specialist centres, will patients elsewhere be able to access it through sample transfer? Will the pathway work for tumours that are difficult to biopsy? Will it add to, or replace, existing tests?
The pilot’s two-year funding window gives a natural evaluation point. If the data show faster turnaround and changed treatment decisions, the case for wider commissioning gets stronger. If the benefit is concentrated in a narrow group, or if laboratory capacity becomes the bottleneck, the honest conclusion may be that the test is valuable but not a system-wide solution.
For now, the safe reading is this: NHS England has launched a serious, funded attempt to move genomic brain tumour testing closer to the patient. It promises speed. The task is to check whether the speed is real, who gets it, and what it changes.